RT Journal Article
SR Electronic
T1 Neurodegeneration in multiple sclerosis
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP S5
OP S12
DO 10.1212/01.wnl.0000275227.74893.bd
VO 68
IS 22 suppl 3
A1 Robert P. Lisak
YR 2007
UL http://n.neurology.org/content/68/22_suppl_3/S5.abstract
AB It is increasingly apparent that neurodegeneration in multiple sclerosis (MS) begins earlier in the course of the disease than was previously believed. The loss of axons, which results in permanent deficits, is distributed beyond regions of abnormal-appearing CNS white matter, and a constant background of neuron loss continues to take place while clinical symptoms wax and wane. It is therefore important to precisely define the scope of neurodegeneration so that experimental and clinical approaches to providing neuroprotective therapies can be devised that will halt and reverse neuron damage. Some of the complexities involved in cellular interactions in the normal-appearing and obviously affected CNS are reviewed here as a starting point for the consideration of approaches to neuroprotective strategies.